{
  "pmid": "26049738",
  "uid": "26049738",
  "title": "The Silence in Hoch et al.'s Commentary about the Rationale for and Objective(s) of Canada's Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers' Dollars.",
  "abstract": "",
  "authors": [
    {
      "last_name": "McDonald",
      "fore_name": "Heather",
      "initials": "H",
      "name": "Heather McDonald",
      "affiliations": [
        "Health Research Methodology (HRM) Program, McMaster University, Hamilton, Canada, heatherpauline@me.com."
      ]
    },
    {
      "last_name": "Charles",
      "fore_name": "Cathy",
      "initials": "C",
      "name": "Cathy Charles",
      "affiliations": []
    },
    {
      "last_name": "Elit",
      "fore_name": "Laurie",
      "initials": "L",
      "name": "Laurie Elit",
      "affiliations": []
    },
    {
      "last_name": "Gafni",
      "fore_name": "Amiram",
      "initials": "A",
      "name": "Amiram Gafni",
      "affiliations": []
    }
  ],
  "journal": {
    "title": "PharmacoEconomics",
    "iso_abbreviation": "Pharmacoeconomics",
    "issn": "1179-2027",
    "issn_type": "Electronic",
    "volume": "33",
    "issue": "8",
    "pub_year": "2015",
    "pub_month": "Aug"
  },
  "start_page": "883",
  "end_page": "886",
  "pages": "883-6",
  "language": "eng",
  "publication_types": [
    "Letter"
  ],
  "keywords": [
    "Antineoplastic Agents",
    "Canada",
    "Disclosure",
    "Humans",
    "Neoplasms",
    "Resource Allocation",
    "Social Responsibility",
    "Taxes",
    "Technology Assessment, Biomedical"
  ],
  "article_ids": {
    "pubmed": "26049738",
    "doi": "10.1007/s40273-015-0297-4"
  },
  "doi": "10.1007/s40273-015-0297-4",
  "dates": {
    "completed": "2016-06-17",
    "revised": "2018-11-13"
  },
  "chemicals": [
    "Antineoplastic Agents"
  ],
  "grants": [],
  "search_metadata": {
    "search_type": "current_affiliation",
    "retrieved_date": "2025-07-30T14:21:51.702072",
    "pmid": "26049738"
  }
}